The publication of the 2011 international consensus criteria by Gorno-Tempini and colleagues marked a critical advancement in the clinical conceptualization of PPA. This framework introduced a classification of PPA into three core clinical variants—nfvPPA, svPPA, and lvPPA, based on specific patterns of speech, language, and neuroimaging findings. These criteria have become widely adopted in research and clinical settings and have provided a much-needed structure for characterizing the linguistic features of progressive aphasia. The core features and main limitations of the 2011 criteria are summarized in Box 1.

However, many individuals with PPA present symptom profiles that do not align neatly with any single variant. So-called mixed or unclassifiable presentations are common, particularly in early disease stages, when deficits are subtle, or in more advanced stages, when deficits may be overlapping with other neurocognitive disorders. This clinical heterogeneity complicates confident classification (Mazzeo et al., 2024a; Utianski et al., 2019; Watanabe et al., 2024) and underscores the need for a more flexible, spectrum-informed framework that accommodates the graded nature of PPA presentation.

One important limitation of the current diagnostic criteria is their applicability to languages other than English. There is a growing body of literature showing that language-specific structural and lexical characteristics can influence PPA phenotypes (e.g., García et al., 2023; Mazzeo et al., 2024b). Therefore, diagnostic criteria should reflect these cross-linguistic and cross-cultural differences.

Moreover, the current criteria emphasize linguistic features while often neglecting broader cognitive, behavioral, or motor symptoms. For instance, patients with nfvPPA may show apraxia of speech, executive dysfunction (Illán-Gala et al., 2024; Macoir et al., 2017a) or parkinsonian signs (Henderson et al., 2024; Santos-Santos et al., 2016), whereas svPPA is frequently associated with behavioral changes (de la Sablonnière et al., 2021) that blur distinctions from the behavioral-variant frontotemporal dementia. Such overlaps, especially in the absence of biomarkers or longitudinal data, can hinder precise diagnosis and delay access to appropriate care. From a clinical management standpoint, diagnostic uncertainty affects prognosis, counseling and access to variant-specific interventions or research protocols. For SLPs, who often lead language assessments, accurate variant identification shapes treatment goals, tool selection, intervention strategies, and the needs for interdisciplinary collaboration. Yet in many non-specialist contexts, SLPs must navigate diagnostic ambiguity with limited standardized resources, increasing variability in care.

A further conceptual limitation is that the current PPA criteria describe deficits in terms of observable clinical manifestations rather than their underlying cognitive mechanisms. For example, the lvPPA is defined partly by impaired sentence repetition, yet the criteria do not specify that this deficit arises primarily from a phonological short-term memory disorder rather than from syntactic or articulatory difficulties. Similarly, agrammatism in nfvPPA or semantic degradation in svPPA may reflect disruptions in distinct cognitive processes that are not explicitly delineated in the diagnostic framework. By focusing on surface-level symptoms instead of the cognitive-functional origins of impairment, the existing criteria may obscure mechanistic distinctions that are essential for understanding, predicting, and targeting disease progression.

In sum, while the 2011 consensus criteria established an invaluable framework, real-world application reveals its limits. Overlapping, evolving, or atypical presentations call for greater diagnostic flexibility and the inclusion of non-linguistic features in variant definitions. Addressing this “syndromic instability” is crucial for timely and accurate diagnosis, equitable care, and the design of personalized interventions.

Importantly, syndromic instability may also reflect the underlying neuropathological heterogeneity of PPA. The same clinical variant can arise from distinct pathological processes, and conversely, identical pathologies can manifest through different linguistic profiles. This clinicopathological dissociation, developed further in Section 2.4, illustrates the need for diagnostic models that move beyond rigid categorical boundaries toward multidimensional, probabilistic frameworks that integrate linguistic, cognitive, and biological markers.

Despite advances in the clinical characterization of PPA, significant barriers persist in clinical practice when assessing language deficits. Chief among these is the limited availability of standardized, efficient, and culturally appropriate diagnostic tools. Most of the widely used batteries, such as the Boston Diagnostic Aphasia Examination (BDAE; Goodglass et al., 2001) in English, or the Batterie d’Évaluation cognitive du Langage (BECLA; Macoir et al., 2016) in French, were originally developed for stroke-induced aphasia and are not optimized for detecting the insidious, variant-specific deficits typical of PPA. They are often time-consuming, require specialized training, and may fail to capture the earliest manifestations of progressive language change.

A further challenge concerns the linguistic and cultural scope of available tools. Most have been created and validated in English-speaking, Western populations, and their direct use in other languages risks bias, reduced sensitivity, and misinterpretation. Tasks relying on culture-specific concepts, lexical frequencies, or morphosyntactic structures may either fail to detect comparable deficits or falsely suggest impairment, forcing clinicians in many regions to rely on non-standardized, informally adapted, or poorly validated instruments.

Orthographic transparency introduces additional complexity: opaque languages such as English or French tend to highlight semantic breakdowns in written tasks (e.g., surface dyslexia or agraphia in svPPA), whereas transparent orthographies, such as Spanish, Italian, or Turkish, may mask or attenuate these impairments unless assessments are carefully adapted to local grapheme–phoneme regularities.

Beyond orthography, core psycholinguistic variables, lexical frequency, word length, morphological complexity, imageability, phonological neighborhood density, and age of acquisition, strongly modulate performance in PPA (Bird et al., 2000; Vonk et al., 2019) but are insufficiently controlled for in many assessment tools. These features shape variant profiles but complicate cross-linguistic adaptation: low-frequency best reveal semantic loss in svPPA (Jefferies and Lambon Ralph, 2006), morphologically and syntactically complex structures expose deficits in nfvPPA (Wilson et al., 2010) and length-dependent repetition demands are particularly sensitive to phonological deficits in lvPPA (Lukic et al., 2019; Macoir et al., 2024). Because such variables differ across languages, assessments lacking matched stimuli or population-specific normative data risk producing misleading results. Box 2 lists key language and psycholinguistic factors that influence assessment accuracy and cross-linguistic comparability.

Beyond linguistic and psycholinguistic considerations, standardized assessment tools themselves present intrinsic limitations increasingly discussed in recent psychometric literature (Swan et al., 2023; Youngstrom et al., 2017). Because normative tests rely on static group-based comparisons, they often fail to capture interindividual trajectories, compensatory mechanisms, or the ecological variability of communication—issues particularly salient in progressive and fluctuating conditions such as PPA. Rigid adherence to population norms may obscure clinically meaningful changes or produce false negatives when age, education, or cultural factors are poorly represented in reference samples. In PPA, these constraints are especially critical, as progressive decline and linguistic diversity challenge the very assumptions underlying standardization. This underscores the need for adaptive, process-oriented, and contextually grounded frameworks that complement norm-based testing and better reflect real-world communication.

Greater investment in culturally sensitive test development, robust norming, and psycholinguistic control is therefore essential for accurate and equitable diagnosis. These challenges are particularly critical for SLPs, who frequently conduct frontline evaluations without access to variant-specific protocols or norms. The absence of brief validated tools adapted to different languages and healthcare systems impedes early detection, longitudinal monitoring, and individualized intervention. Although tools such as the Mini Linguistic State Examination (MLSE; Patel et al., 2022), the Detection Test for Language Impairments in Adults and the Aged (DTLA; Macoir et al., 2017b) and the Progressive Aphasia Severity Scale (PASS; Sapolsky et al., 2014), show promise, their dissemination beyond research centers remains limited. Few existing tools offer multidimensional profiling in a time-efficient format.

A coordinated international effort is urgently needed to design and share brief, psychometrically robust, and culturally adaptable assessments. Such tools would not only enhance early diagnosis and treatment planning but also promote equity and comparability across populations. Equally crucial, future research should emphasize clinical approaches that capture individual trajectories, within-person variability, and the real-world functional impact of communication impairments. This requires greater openness to criterion-referenced and process-oriented methods, including descriptive analyses and language-sample–based assessments, which can track progressive change and compensatory adaptation more sensitively than norm-based tests alone. Recent longitudinal and speech-analysis studies support this need for trajectory-sensitive, process-oriented approaches that extend beyond static norm-based tools (Ash et al., 2019; Yeung et al., 2021; Gallée et al., 2023). Combining standardized and individualized approaches represents a promising path toward more ecological, person-centered evaluation of language in neurodegenerative conditions such as PPA.

Distinguishing PPA from other neurocognitive and psychiatric conditions remains a central clinical challenge. At initial presentation, language impairments may be subtle, variable, or overshadowed by behavioral and emotional symptoms (Marshall et al., 2018; Ruksenaite et al., 2021), leading to misdiagnosis and delayed intervention. Box 3 provides a concise overview contrasting each PPA variant with its closest diagnostic look-alikes.

The lvPPA exemplifies this difficulty. Patients exhibit word-finding pauses and phonological errors (Gorno-Tempini et al., 2011) that can resemble the anomia and working-memory limitations of early AD (Huntley and Howard, 2010; Pistono et al., 2019). Without detailed linguistic assessment, lvPPA can be mistaken for amnestic AD, a clinically consequential error, as the two conditions share identical pharmacological treatment yet differ in symptom trajectories, progression patterns, and support needs. Diagnostic confusion may also arise between lvPPA and nfvPPA, particularly early in the disease, when both may present with speech that appears slowed or interrupted by pauses. However, in lvPPA, these pauses reflect word-finding difficulty and reduced phonological short-term memory, whereas in nfvPPA they result from motor speech impairment and agrammatism (Lukic et al., 2019; Macoir et al., 2021).

svPPA presents another diagnostic pitfall. Alongside the progressive erosion of conceptual knowledge and word meaning, patients frequently develop behavioral and socio-emotional changes such as loss of empathy, rigid or compulsive behaviors, and altered dietary preferences (Foxe et al., 2022; Roy et al., 2023). These features overlap with behavioral variant frontotemporal dementia (Kamath et al., 2019; Ramanan et al., 2022) and may also be misinterpreted as depression (Szymkowicz et al., 2023) in non-specialist settings, delaying appropriate recognition of the underlying language disorder.

In nfvPPA, diagnosis can be challenging when motor-speech impairments—particularly apraxia of speech—predominate particularly apraxia of speech. Such cases may first be labeled primary progressive apraxia of speech (PPAOS) (Duffy et al., 2021) or mistaken for movement disorders such as progressive supranuclear palsy or corticobasal syndrome (Krzosek et al., 2022; Peterson et al., 2021) which may later co-occur. Emerging evidence suggests that nfvPPA and PPAOS may lie along a shared continuum, displaying overlapping features yet maintaining distinct onset profiles and evolutionary trajectories (Duffy et al., 2021; Garcia-Guaqueta et al., 2024; Illán-Gala et al., 2024; Lorca-Puls et al., 2023).

Accurate differential diagnosis therefore requires the synthesis of detailed language testing, comprehensive neuropsychological profiling, and longitudinal observation. Although follow-up can eventually clarify uncertain cases, delays in classification postpone access to appropriate counseling and therapy. Moreover, as disease progresses and additional cognitive, behavioral and motor deficits emerge, distinguishing between the three PPA variants becomes increasingly challenging, reinforcing the need for timely, early-stage identification. Early, accurate identification, based on standardized linguistic assessment and diverse interpretive approaches (norm-referenced, criterion-referenced, dynamic, and descriptive) and informed by multidisciplinary input, is essential both for optimal care and for inclusion in research trials targeting variant-specific mechanisms.

While careful clinical assessment is essential for distinguishing PPA from other neurocognitive and psychiatric conditions, even accurate syndromic classification provides only a partial picture. One of the defining complexities of PPA One of the defining complexities of PPA lies in its neuropathological heterogeneity. Unlike post-stroke aphasia, which is tied to a focal vascular lesion, PPA can result from diverse underlying pathologies, most commonly FTLD or AD (Gorno-Tempini et al., 2011; Mesulam et al., 2014a; Mesulam et al., 2014b). Crucially, the relationship between clinical presentation and underlying disease is not one-to-one: the same PPA variant may arise from different biological processes. For example, nonfluent/agrammatic PPA may be caused by either FTLD-tau or FTLD-TDP (Grossman, 2010; Rusina et al., 2022), while a single pathology such as AD can manifest through multiple phenotypes, most often the lvPPA but occasionally others (Mesulam et al., 2014a; Mesulam et al., 2014b). This clinicopathological dissociation complicates prognosis, counseling, and efforts to develop targeted interventions. Current and future biomarker strategies are overviewed in Box 4.

Broad associations between clinical subtypes and pathology have been described but remain imperfect. svPPA is most consistently linked to FTLD-TDP type C, although a minority of cases show tau pathology (Ma et al., 2025; Mesulam et al., 2014a; Mesulam et al., 2014b). nfvPPA is heterogeneous, with underlying pathology divided between FTLD-tau (including progressive supranuclear palsy and corticobasal syndrome) and FTLD-TDP (Giannini et al., 2019; Montembeault et al., 2018). lvPPA is most often associated with AD pathology (Bergeron et al., 2018), but cases related to FTLD have also been reported (Mesulam et al., 2022; Shir et al., 2024), and recent imaging evidence suggests that Lewy body disease may occasionally contribute to amyloid-negative presentations (Kang et al., 2025). These probabilistic can assist clinical reasoning but do not provide diagnostic certainty at the individual level.

Structural MRI and FDG-PET reveal characteristic but overlapping patterns of atrophy or hypometabolism (e.g., anterior temporal for svPPA, left inferior frontal/insula for nfvPPA, and left temporoparietal for lvPPA) (Mirbod et al., 2024). However, these imaging signatures are not pathognomonic: while anterior temporal atrophy is typical of svPPA, it is also observed in right-anterior-temporal–predominant FTD, a syndrome clinically distinguishable from svPPA (Eldaief et al., 2023; Ulugut et al., 2024). Likewise, temporoparietal atrophy, although considered a hallmark of lvPPA, is also frequently observed in atypical presentations of AD without aphasia, such as posterior cortical atrophy or dysexecutive variants, limiting its diagnostic specificity (Townley et al., 2020; Whitwell et al., 2018).

Despite their diagnostic value, advanced biomarkers remain unevenly available across clinical settings. PET imaging is costly and often restricted to research centers (Rabinovici et al., 2025). Lumbar puncture is not consistently available and is often perceived as an invasive procedure. Moreover, many clinicians remain insufficiently trained to interpret CSF profiles or unconvinced of the added clinical value of biomarker confirmation (Bouwman et al., 2022; Hampel et al., 2022). Access is especially limited in low- and middle-income countries, where uneven diffusion of biomarker technology compounds existing cross-linguistic and cross-cultural inequities in diagnosis and research participation (Babulal et al., 2024; McGlinchey et al., 2024). Importantly, these biomarkers are most sensitive to AD pathology and therefore particularly useful for identifying AD-related lvPPA (Iaccarino et al., 2023; Rullmann et al., 2025).

Given these challenges, no single biomarker currently provides a reliable and universally applicable method for distinguishing among PPA variants or predicting progression. Future progress will likely depend on multimodal approaches that integrate clinical, neuropsychological, neuroimaging, and biological data. Promising developments include blood-based biomarkers such as plasma phosphorylated tau and neurofilament light chain, which may broaden access by reducing cost and invasiveness (Grande et al., 2025; Liampas et al., 2024). Machine learning models that combine multimodal data, including language performance, structural and functional imaging, and biomarker measures (Rezaii et al., 2024; Tafuri et al., 2024), show growing potential for improving individual-level prediction of underlying pathology (for a review, see Macoir et al., 2025).

The accurate diagnosis of PPA often depends on coordinated input from a multidisciplinary team that typically includes neurologists, nurses, SLPs, and neuropsychologists. Such collaborative expertise is most often found in tertiary memory or language clinics, yet access to these centers is uneven both within and across countries (Gallée et al., 2024; Gulline et al., 2025). Patients in rural areas or low-resource regions frequently encounter substantial delays before being referred to specialized services, if referral occurs at all (Villaseñor and Saidi, 2024). Box 5 highlights the main challenges and priority action related to inequitable access to clinical expertise and training in PPA diagnosis.

A further challenge lies in the limited awareness and training of clinicians and allied health professionals. Surveys and practice reports indicate that many neurologists, geriatricians, and SLPs receive little formal instruction on recognizing the early language-led presentations of neurodegenerative disease. This lack of formation is particularly pronounced for PPA, which remains underrepresented in most medical and speech-language pathology curricula (Battista et al., 2023; Gallée et al., 2024). Training programs and diagnostic pathways continue to emphasize amnestic AD, predisposing clinicians to overlook or misinterpret progressive language symptoms (Giebel et al., 2024). As a result, early manifestations of PPA may be attributed to normal aging, psychiatric conditions such as depression or anxiety (Mulder-Heijstra et al., 2022), or classified under nonspecific dementia labels, preventing patients from receiving variant-specific management and support (Hall et al., 2013).

These knowledge gaps have direct consequences for patient care. Underdiagnosis or misdiagnosis leads to delays in counseling, limits opportunities for time –sensitive speech-language intervention and impedes access to research protocols and clinical trials (Battista et al., 2023; Mouton et al., 2022). Even when PPA is recognized, variability in clinical experience means that care pathways can differ considerably from one region to another, with some patients receiving comprehensive multidisciplinary support and others relying on informal assessments or generic dementia management strategies (Gallée et al., 2024).

Addressing this inequity requires both systemic and educational responses. Integrating PPA more thoroughly into medical and speech-language pathology curricula, disseminating consensus diagnostic guidelines, and developing accessible, standardized brief assessment protocols could substantially improve early recognition. Telemedicine (Yi et al., 2021) and international training initiatives (Gallée et al., 2024) may also help extend specialist expertise to regions without tertiary centers. Without such measures, disparities in professional training and clinical access will continue to widen inequities in PPA diagnosis and care.

The clinical consequences of these limitations are far-reaching. Delayed or inaccurate diagnosis often results in missed opportunities for early intervention and communication-focused therapy, at a stage when compensatory tools and strategies, relying on preserved capacities, are most effective (Marshall et al., 2018). Patients and families may not receive timely counseling, support for daily communication, or guidance on planning for disease progression (Shibata et al., 2024). Inaccurate or nonspecific diagnoses can also exclude individuals from clinical research or variant-targeted treatment trials. In contrast, early recognition enables clinicians to implement tailored speech-language interventions, educate caregivers, and facilitate access to appropriate medical and social resources, thereby enhancing quality of life and ensuring greater continuity of care.

Earlier and more reliable recognition of PPA depends on stronger and more widespread professional training. Instruction on language-led neurodegenerative presentations should be incorporated into neurology, geriatrics, and speech-language-pathology curricula to correct the prevailing bias toward amnestic AD and help clinicians detect subtle, language-dominant syndromes. Continuing-education programs, teleconsultation networks, and online modules can disseminate expertise to clinicians in low-resource or rural areas, thus reducing geographic inequities. Broader awareness of variant-specific features will minimize misclassification and improve referrals. Professional associations and health ministries should support certification or microcredential pathways focused on PPA, promoting multidisciplinary collaboration among neurologists, neuropsychologists, and SLPs to embed PPA within standard dementia-care frameworks.

Global equity requires standardized, linguistically valid tools reflecting structural and orthographic differences across languages. International collaborations should prioritize the adaptation and validation of brief screening measures, the creation of robust normative datasets, and the integration of psycholinguistic controls in test design. Open-access repositories of multilingual stimuli, scoring guides, and normative databases—modeled after initiatives in stroke aphasia or neuropsychology—would accelerate progress and prevent duplication. Harmonized cross-linguistic datasets will enhance generalizability and support robust meta-analyses and universal diagnostic metrics.

More than a decade after publication, the 2011 international consensus criteria (Gorno-Tempini et al., 2011) remain foundational but increasingly outdated. Mixed or atypical profiles, syndromic instability, and clinicopathological dissociation justify an updated, more flexible model integrating linguistic, cognitive, behavioral, imaging, and biomarker indicators. A revised consensus should: (a) define core and ancillary features along continua rather than categorical cut-offs; (b) incorporate quantifiable psycholinguistic metrics (e.g., lexical diversity, syntactic complexity); (c) recommend standardized brief core batteries; and (d) include updated biomarker-supported diagnostic tiers analogous to Alzheimer’s frameworks.

Future diagnostic frameworks should combine clinical, neuropsychological, linguistic, imaging, and biological data into coherent into coherent multimodal pipelines. Blood-based biomarkers such as plasma phosphorylated tau and neurofilament light chain offer less-invasive complements to CSF and PET studies (Grande et al., 2025; Liampas et al., 2024). Integrating these markers with digital linguistic features and advanced imaging indices could improve individualized prediction of underlying pathology. Machine-learning approaches merging linguistic, neuroimaging, and biomarker inputs show strong potential for variant classification and disease monitoring (Rezaii et al., 2024; Tafuri et al., 2024), but clinical translation requires transparent algorithms, shared datasets, and standardized interpretive guidelines. Cross-institutional collaboration and open-science practices, including data sharing, preregistration, and reproducible pipelines, will be essential for validation and bias reduction.

Early, accurate diagnosis must guide personalized intervention. PPA patients should access evidence-based therapies tailored to each variant’s linguistic and cognitive profile. Priorities include (a) compensatory communication strategies (Cadório and Vieira, 2025); (b) variant-specific approaches such as conversational coaching for lvPPA or lexical-retrieval treatment for svPPA (Pagnoni et al., 2021; Simic et al., 2025); and (c) caregiver training and counseling to foster supportive communication environments (Wong et al., 2025). Integrated care pathways linking neurology, speech-language pathology, neuropsychology, and social work should ensure continuity. Recognizing people with PPA as a target population for early intervention would legitimize these services and facilitate reimbursement. Early identification improves outcomes and expands access to clinical and disease-modifying trials.

Global collaboration is essential to accelerate progress. Shared behavioral, imaging, and biomarker databases will improve reproducibility and cross-validation of diagnostic models. Multicenter studies must include linguistically and culturally diverse populations avoiding the historical over-representation of English-speaking cohorts. Longitudinal designs tracking progression across variants are needed to refine prognostic markers and treatment timing. Open-science frameworks, preregistration, transparent data curation, and FAIR-compliant repositories, will ensure that datasets are globally accessible and ethically shared. Such collaboration can transform PPA diagnosis from a fragmented field into a cohesive, internationally integrated enterprise.